Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC)

Cancer Treatment Reviews

Volumn 38, Issue 3, 2012, Pages 173-184

  Belani, C P ^a   Goss, G ^b   Blumenschein, G ^c  

^a PENN STATE CANCER INSTITUTE   (United States)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Biomarkers; NSCLC; Personalized therapy; Signalling; Targeted agents

Indexed keywords

AFATINIB; AFLIBERCEPT; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; CRIZOTINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FIGITUMUMAB; GEFITINIB; GEMCITABINE; MOTESANIB; NAVELBINE; PACLITAXEL; PEGVISOMANT; PEMETREXED; PF 0299804; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR;

ADD ON THERAPY; ANTINEOPLASTIC ACTIVITY; APPETITE; CANCER COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG SYNTHESIS; DRUG WITHDRAWAL; HUMAN; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; STOMATITIS; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84857658325     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.05.009     Document Type: Review

References (102)

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: NSCLC v.2.2009. http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf.
2. Yang C.-H., Fukuoka M., Mok T.S., et al. Final overall survival (OS) results from a phase III randomised open-label, first-line study of gefitinib (G) v carboplatin/paclitaxel (C/P) in clinically selected patients with advanced nonsmall cell lung cancer (NSCLC) in Asia (IPASS). Ann Oncol 2010, 21(Suppl. 8):viii1. [abstr LBA2].
3. Gatzemeier U., Eisen T., Santoro A., et al. Sorafenib (S) + gemcitabine/cisplatin (GC) vs GC alone in the first-line treatment of advanced non-small cell lung cancer (NSCLC): phase III NSCLC research experience utilizing sorafenib (NEXUS) trial. Ann Oncol 2010, 21(Suppl. 8):viii7. [abstr LBA16].
4. Miller V.A., Hirsh V., Cadranel J., et al. Phase IIB/III double-blind randomized trial of afatinib (BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2) + best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib (LUX-LUNG 1). Ann Oncol 2010, 21(Suppl. 8):viii1. [abstr LBA1].
5. Shaw A.T., Yeap B.Y., Mino-Kenudson M., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27:4247-4253.
6. Keedy V.L., Sandler A.B. Inhibition of angiogenesis in the treatment of non-small cell lung cancer. Cancer Sci 2007, 98:1825-1830.
7. Pennell N.A., Lynch T.J. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 2009, 14:399-411.
8. Scagliotti G.V. Potential role of multi-targeted tyrosine kinase inhibitors in non-small-cell lung cancer. Ann Oncol 2007, 18(Suppl. 10):x32-x41.
9. Schiller J.H., Larson T., Ou S.I., et al. Efficacy and safety of axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II trial. J Clin Oncol 2007, 25(Suppl. 18). [abstr 7507].
10. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
11. Reck M., von Pawel J., Zatloukal P., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009, 27:1227-1234.
12. Crino L., Franke F., Sadjadian P., et al. Final safety outcomes by chemotherapy (CT) regimen for the MO19390 (SAIL) trial: first-line bevacizumab (BV)-based therapy in advanced nonsmall cell lung cancer (NSCLC). Ann Oncol 2010, 21(Suppl. 8):viii143. [abstr 427P].
13. Khambata-Ford S., Harbison C., Woytowitz D., et al. K-Ras mutation (mut), EGFR-related, and exploratory markers as response predictors of cetuximab in first-line advanced NSCLC: retrospective analyses of the BMS099 trial. J Clin Oncol 2009, 27(Suppl. 15). [abstr 8021].
14. Pirker R., Pereira J.R., Szczesna A., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373:1525-1531.
15. Shepherd F.A., Rodrigues P.J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
16. Herbst R.S., Prager D., Hermann R., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:5892-5899.
17. Gatzemeier U., Pluzanska A., Szczesna A., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva lung cancer investigation trial. J Clin Oncol 2007, 25:1545-1552.
18. Cappuzzo F., Ciuleanu T., Stelmakh L., et al. SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol 2009, 27(Suppl. 15):407s. [abstr 8001].
19. Zhou C., Wu Y.L., Chen C., et al. Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced non small-cell lung cancer (NSCLC) patients (PTS) with EGFR activating mutations. Ann Oncol 2010, 21(Suppl. 8):viii6. [abstr LBA13].
20. Karp D.D., Novello S., Cardenal F., et al. Continued high activity of figitumumab (CP-751, 871) combination therapy in squamous lung cancer. J Clin Oncol 2009, 27(Suppl. 15). [abstr 8072].
21. Jassem J., Langer C.J., Karp D., et al. Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28(Suppl. 15). [abstr 7500].
22. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
23. Herbst R.S., Giaccone G., Schiller J.H., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004, 22:785-794.
24. Giaccone G., Herbst R.S., Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004, 22:777-784.
25. Kim E.S., Hirsh V., Mok T., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
26. Blumenschein G.R., Kabbinavar F.F., Menon H., et al. Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28(Suppl. 15). [abstr 7528].
27. 27. Bayer HealthCare and Onyx Pharmaceuticals press release. 2010. Final analysis of the Phase III NExUS (NSCLC research Experience Utilizing Sorafenib) trial evaluating sorafenib in combination with gemcitabine and cisplatin in patients with advanced non-squamous, non-small cell lung cancer (NSCLC).
28. Novello S., Scagliotti G.V., Rosell R., et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 2009, 101:1543-1548.
29. Socinski M.A., Novello S., Brahmer J.R., et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008, 26:650-656.
30. Scagliotti G.V., Krzakowski M., Szczesna A., et al. Sunitinib (SU) in combination with erlotinib (E) for the treatment of advanced/metastatic nonsmall cell lung cancer (NSCLC): a phase III study. Ann Oncol 2010, 2(Suppl. 8):viii3.
31. Groen H.J., Socinski M.A., Grossi F., et al. Randomized phase II study of sunitinib (SU) plus erlotinib (E) vs. placebo (P) plus E for the treatment of metastatic non-small cell lung cancer (NSCLC). Ann Oncol 2010, 21(Suppl. 8):viii122.
32. Heymach J., Paz-Ares L., De Braud F., et al. Randomized phase II study of vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007, 25(Suppl. 18). [abstr 7544].
33. Heymach J.V., Johnson B.E., Prager D., et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007, 25:4270-4277.
34. Natale R.B., Thongprasert S., Greco F.A., et al. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST). J Clin Oncol 2009, 27(Suppl. 15). [abstr 8009].
35. Herbst R.S., Sun Y., Eberhardt W.E., et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010, 11:619-626.
36. De Boer R., Arrieta O., Gottfried M., et al. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZEAL). J Clin Oncol 2009, 27(Suppl. 15). [abstr 8010].
37. Lee J., Hirsh V., Park K., et al. Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2010, 28(Suppl. 15). [abstr 7525].
38. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002, 29:15-18.
39. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
40. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003, 3:401-410.
41. Cao R., Brakenhielm E., Li X., et al. Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-alphaalpha and -alphabeta receptors. FASEB J 2002, 16:1575-1583.
42. Shikada Y., Yonemitsu Y., Koga T., et al. Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas. Cancer Res 2005, 65:7241-7248.
43. Ramalingam S.S., Dahlberg S.E., Langer C.J., et al. Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study. J Clin Oncol 2007, 25(Suppl. 18). [abstr 7535].
44. Griesinger F., Laskin J.J., Pavlakis N. And the MO19390(SAiL) Study Group. Safety of first-line bevacizumab-based therapy with concomitant cardiovascular or anticoagulation medication in advanced or recurrent non-squamous non-smallcell lung cancer (NSCLC) in MO19390 (SAiL). J Clin Oncol 2008, 26(Suppl. 15). [abstr 8049].
45. Gordon M.S., Margolin K., Talpaz M., et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001, 19:843-850.
46. Crinò L., Dansin E., Garrido P., et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010, 11:733-740.
47. Besse B., Lasserre S.F., Compton P., et al. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 2010, 16:269-278.
48. De Braganca K.C., Janjigian Y.Y., Azzoli C.G., et al. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J Neurooncol 2010, 100(3):443-447.
49. Avastin, summary of product characteristics. 2009. F. Hoffmann-La Roche Ltd.
50. Chu Q.S. Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther 2009, 9:263-271.
51. Goss G., Shepherd F.A., Laurie S., et al. A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 2009, 45:782-788.
52. Goss G.D., Arnold A., Shepherd F.A., et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 2010, 28:49-55.
53. Potapova O., Laird A.D., Nannini M.A., et al. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther 2006, 5:1280-1289.
54. Blais N., Page R.D., Hainsworth J.D., et al. Sunitinib malate as maintenance therapy in patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC): a phase II study. Ann Oncol 2008, 19(Suppl. 8):viii89.
55. Robert F., Sandler A., Schiller J.H., et al. Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study. Cancer Chemother Pharmacol 2010, 66:669-680.
56. Reck M., Frickhofen N., Cedres S., et al. Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study. Lung cancer 2010, 70:180-187. [Epub 2010 Feb 25].
57. Chow L.Q., Jonker D.J., Laurie S.A., et al. Sunitinib (SU) in combination with pemetrexed (P) in patients (pts) with advanced solid malignancies: a phase I dose escalation study. J Clin Oncol 2008, 26(Suppl. 15):3566.
58. Gridelli C., Maione P., Del Gaizo F., et al. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist 2007, 12:191-200.
59. Schiller J.H., Lee J., Hanna N., et al. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens. J Clin Oncol 2008, 26(Suppl. 15):427S.
60. Blumenschein G.R., Gatzemeier U., Fossella F., et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:4274-4280.
61. Scagliotti G., Novello S., von Pawel J., et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:1835-1842.
62. Polverino A., Coxon A., Starnes C., et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006, 66:8715-8721.
63. Perrotte P., Matsumoto T., Inoue K., et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999, 5:257-265.
64. Hirsch F.R., Varella-Garcia M., Bunn P.A., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21:3798-3807.
65. Brugger W., Triller N., Blasinska-Morawiec M., et al. Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC. J Clin Oncol 2009, 27(Suppl. 15). [abstr 8020].
66. Fukuoka M., Wu Y., Thongprasert S., et al. Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS). J Clin Oncol 2009, 27(Suppl. 15). [abstr 8006].
67. Sequist L.V., Bell D.W., Lynch T.J., et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007, 25:587-595.
68. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
69. Pao W., Miller V.A., Politi K.A., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73.
70. Sequist L.V., Martins R.G., Spigel D., et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008, 26:2442-2449.
71. Spigel D., Ervin T., Ramlau R., et al. Randomized multicenter double-blind placebo controlled phase II study evaluating MetMAb, an antibody to met receptor, in combination with erlotinib, in patients with advanced non-small cell lung cancer. Ann Oncol 2010, 21(Suppl. 8):viii7. [abstr LBA15].
72. Shigematsu H., Lin L., Takahashi T., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005, 97:339-346.
73. Cappuzzo F., Ciuleanu T., Stelmakh L., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521-529.
74. Cappuzzo F., Ciuleanu T., Park K., et al. Erlotinib maintenance therapy in patients with stable disease after first-line platinum doublet chemotherapy for advanced NSCLC. Ann Oncol 2010, 21(Suppl. 8):viii124. [abstr 369PD].
75. Lee S., Rudd R.M., Khan I., et al. TOPICAL: randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy. J Clin Oncol 2010, 28(Suppl. 15). [abstr 7504].
76. Inoue A., Minegishi Y., Maemondo M., et al. Final results of a phase II study of first-line gefitinib for elderly patients (PTS) with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations; NEJ 003 study. Ann Oncol 2010, 21(Suppl. 8):viii141. [abstr 423P].
77. Engelman J.A., Zejnullahu K., Gale C.M., et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007, 67:11924-11932.
78. Ramalingam S.S., Boyer M., Park K., et al. Randomized phase 2 study of PF299804, an irreversible human epidermal growth factor receptor (EGFR) inhibitor, versus (V) erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) after chemotherapy (CT) failure: quantitative and qualitative benefits. Ann Oncol 2010, 21(Suppl. 8):viii122. [abstr 365].
79. Mok T., Spigel D.R., Park K., et al. Efficacy and safety of PF299804 as first-line treatment (TX) of patients (PTS) with advanced (ADV) NSCLC selected for activating mutation (MU) of epidermal growth factor receptor (EGFR). Ann Oncol 2010, 21(Suppl. 8):viii8. [abstr LBA18].
80. Ryan P.D., Goss P.E. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 2008, 13:16-24.
81. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008, 8:915-928.
82. Kong D., Yamori T. Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. Cancer Sci 2008, 99:1734-1740.
83. Milton D.T., Riely G.J., Azzoli C.G., et al. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer 2007, 110:599-605.
84. Lacy M.Q., Alsina M., Fonseca R., et al. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751, 871 in patients with multiple myeloma. J Clin Oncol 2008, 26:3196-3203.
85. Corral J., Sanchez-Torrez J., O'Byrne K., et al. Phase I study of the IGF-IR inhibitor figitumumab (CP-751, 871) in combination with cisplatin and gemcitabine or cisplatin and pemetrexed in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2010, 5(Suppl. 1):S85.
86. Hanna N., Goodgame B., Oakhill G., et al. Safety and pharmacokinetics of first-line AMG 479 in combination with paclitaxel and carboplatin (PC) for advanced, squamous non-small cell lung cancer (NSCLC). Ann Oncol 2010, 21(Suppl. 8):viii158. [abstr 482].
87. Soda M., Choi Y.L., Enomoto M., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
88. Christensen J.G., Zou H.Y., Arango M.E., et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007, 6:3314-3322.
89. McDermott U., Iafrate A.J., Gray N.S., et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008, 68:3389-3395.
90. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
91. Sequist L.V., Alkerley W.L., Brugger W., et al. Final results from ARQ197-209: a global randomized placebo-controlled phase 2 clinical trial of erlotinib PLUS ARQ197 versus erlotinib plus placebo in previously treated EGFR-inhibitor naïve patients with advanced non-small cell lung cancer (NSCLC). Ann Oncol 2010, 21(Suppl. 8):viii122. [abstr 363O].
92. Herbst R.S., Sandler A. Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC. Oncologist 2008, 13:1166-1176.
93. Herbst R.S., O'Neill V.J., Fehrenbacher L., et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007, 25:4743-4750.
94. Hainsworth J., Herbst R. A phase III, multicenter, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy of bevacizumab (Avastin) in combination with erlotinib (Tarceva) compared with erlotinib alone for treatment of advanced non-small cell lung cancer after failure of standard first-line chemotherapy. J Thorac Oncol 2008, 3(Suppl. 4):S302.
95. Miller V.A., O'Connor P., Soh C., Kabbinavar F. A randomized, double-blind, placebo controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic NSCLC. J Clin Oncol 2009, 27(Suppl. 18):799s. [abstr 8002].
96. Kabbinavar F., Miller V.A., Johnson B.E., et al. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28(Suppl. 15). [abstr 7526].
97. Bonomi P.D., Mace J., Mandanas R.D., et al. Phase II randomized, open-label study of cetuximab (Cet) and bevacizumab (Bev) in combination with paclitaxel (P) and carboplatin (C) in patients with stageIII/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2009, 27(Suppl. 15). [abstr 8046].
98. Gandara D., Kim E.S., Herbst R.S., et al. S0536: carboplatin, paclitaxel, cetuximab and bevacixumab followed by cetuximab and bevacizumab maintenance in advanced NSCLC: a SWOG phase II study. J Clin Oncol 2009, 27(Suppl. 15):410s. [abstr 8015].
99. Wedge S.R., Ogilvie D.J., Dukes M., et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002, 62:4645-4655.
100. Lind J.S., Dingemans A.C., Groen H.J., Smit E.F. A phase II study of erlotinib and sorafenib in chemotherapy-naive patients with locally advanced/metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2009, 27(Suppl. 15). [abstr 8018].
101. Gridelli C., Morgillo F., Favaretto A., et al. Gemcitabine or erlotinib in combination with sorafenib in elderly patients with advanced non small cell lung tumor (GEST): a randomized phase II study. Ann Oncol 2010, 21(Suppl. 8):viii141. [abstr 422P].
102. Calvo E., Ma W., Tolcher A., et al. Phase I study of PF299804 combined with figitumumab (CP-751, 871) in patients with advanced solid tumors. J Clin Oncol 2010, 28(Suppl. 15). [abstr 3026].